Lexaria Bioscience Corp. LEXX
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Lexaria Bioscience Corp. (LEXX) is a healthcare company listed in the US with a market value of about $9M. In the twelve months to May 31, 2026 it had revenue of $194000 and net income of -$8M, a net margin of -3985.6%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 13% a year, a 5-year average ROIC of -129%.
About Lexaria Bioscience
Lexaria Bioscience is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $14702 in 2015 to $705923 in 2025, growth of about 47.3% a year. It was profitable in 0 of the last 10 years in our data. It spends 1167% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $194000 | $705923 | $464278 | $86380 | $255397 | $722738 | $384543 | $222610 | $433287 | $63639 | $40718 |
| Net income | -$8M | -$12M | -$6M | -$7M | -$7M | -$4M | -$4M | -$4M | -$7M | -$2M | -$1M |
| Free cash flow | -$7M | -$10M | -$5M | -$6M | -$5M | — | -$3M | -$4M | — | -$2M | -$663950 |
| EPS (diluted) | $-0.34 | $-0.66 | $-0.47 | $-1.01 | — | $-0.95 | $-1.47 | $-1.50 | $-2.70 | $-0.90 | $-0.90 |
| Net margin | -3985.6% | -1686.0% | -1248.2% | -7715.8% | -2846.3% | -557.2% | -1062.2% | -1868.0% | -1525.4% | -3031.9% | -3136.8% |
| ROIC | — | -302.9% | -55.6% | -169.6% | -83.3% | -33.8% | -125.1% | -124.0% | -276.7% | -69.6% | -410.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Lexaria Bioscience pay a dividend?
Not currently.
Is Lexaria Bioscience a good stock to buy?
We do not give buy or sell advice. Lexaria Bioscience scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.